Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 106 citing Tsuchida: Peroxisome Proliferator–Activated Receptor (PPAR) α Activation Increases Adiponectin.... (0.08 sec) 

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the …

- nih.gov
T Kadowaki, T Yamauchi, N Kubota, K … - Journal of Clinical …, 2006 - Am Soc Clin Investig
Adiponectin is an adipokine that is specifically and abundantly expressed in adipose tissue and
directly sensitizes the body to insulin. Hypoadiponectinemia, caused by interactions of genetic
factors such as SNPs in the Adiponectin gene and environmental factors causing obesity, ...
Cited by 411 - Related articles - BL Direct - All 9 versions

[PDF] Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin …


T Yamauchi, Y Nio, T Maki, M Kobayashi, T … - Nature - xn-- …
Page 1. 332 VOLUME 13 | NUMBER 3 | MARCH 2007 NATURE MEDICINE Targeted
disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and
metabolic actions Toshimasa Yamauchi 1–3,7 ,Yasunori ...
Cited by 170 - Related articles - View as HTML - BL Direct - All 10 versions

Peroxisome Proliferator-Activated Receptor {gamma} and Adipose Tissue-- …

- endojournals.org
AM Sharma, B Staels - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc
Conclusions: PPAR is highly expressed in adipose tissue, where its activation with thiazolidinediones
alters fat topography and adipocyte phenotype and up-regulates genes involved in fatty acid
metabolism and triglyceride storage. Furthermore, PPAR activation is associated with ...
Cited by 99 - Related articles - BL Direct - All 3 versions

Endocrine regulation of the fasting response by PPARα-mediated induction of …

- cell.com
T Inagaki, P Dutchak, G Zhao, X Ding, L Gautron, V … - Cell metabolism, 2007 - Elsevier
Peroxisome proliferator-activated receptor α (PPARα) regulates the utilization of fat as an energy
source during starvation and is the molecular target for the fibrate dyslipidemia drugs. Here, we
identify the endocrine hormone fibroblast growth factor 21 (FGF21) as a mediator of the ...
Cited by 97 - Related articles - All 10 versions

Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential …


MJ Yoon, GY Lee, JJ Chung, YH Ahn, SH Hong, JB … - Diabetes, 2006 - Am Diabetes Assoc
Adiponectin has recently received a great deal of attention due to its beneficial effects on insulin
resistance and metabolic disorders. One of the mechanisms through which adiponectin exerts
such effects involves an increase in fatty acid oxidation in muscle and liver. In the present ...
Cited by 84 - Related articles - BL Direct - All 6 versions

PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the …


C Fiévet, JC Fruchart, B Staels - Current Opinion in Pharmacology, 2006 - Elsevier
The discovery of the crucial role of peroxisome proliferator-activated receptors (PPARs) as regulators
of lipid and glucose metabolism has raised interest in the development of synthetic ligands as
potential tools for therapeutic intervention in type 2 diabetes and the metabolic syndrome. ...
Cited by 56 - Related articles - All 2 versions

Innate immunity modulates adipokines in humans

- endojournals.org
PD Anderson, NN Mehta, ML Wolfe, CC Hinkle, … - Journal of Clinical …, 2007 - Endocrine Soc
Context: Chronic inflammation converges in type 2 diabetes and atherosclerosis. Modulation
of adipokine signaling by innate immunity in humans is of considerable interest given the role
of adipokines in insulin resistance and atherosclerosis. ... Objective: The aim of the study ...
Cited by 46 - Related articles - BL Direct - All 4 versions

Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the …


B Pourcet, JC Fruchart, B Staels, C … - Expert Opin. Emerging …, 2006 - informahealthcare.com
More than 70% of patients with Type 2 diabetes mellitus (T2DM) die because of cardiovascular
diseases. Current therapeutic strategies are based on separate treatment of insulin resistance
and dyslipidaemia. Development of drugs with multimodal activities should improve ...
Cited by 40 - Related articles - BL Direct - All 6 versions

Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and …

- ahajournals.org
A Hiuge, A Tenenbaum, N Maeda, M … - … , and vascular biology, 2007 - Am Heart Assoc
From Department of Metabolic Medicine (AH, NM, MK, TH, KF, HN, SK, IS, TF), Graduate School
of Medicine, Osaka University, Osaka, Japan; Cardiac Rehabilitation Institute (AT, EZF, YA,
MM), The Israel Society for the Prevention of Hearth Attacks (ISPHA) (MB, DT, SB), the ...
Cited by 39 - Related articles - All 8 versions

Adiponectin: an update


M Guerre-Millo - Diabetes and Metabolism, 2008 - Elsevier
The discoveries of leptin and adiponectin were breakthroughs in the field of metabolic
diseases. Adipose cells produce both proteins and release them into the circulation. Leptin acts
as a fundamental signal for the brain to modulate food intake as a function of energy ...
Cited by 36 - Related articles - BL Direct - All 2 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google